A novel Affibody bioconjugate for dual-modality imaging of ovarian cancer.

@article{Wang2014ANA,
  title={A novel Affibody bioconjugate for dual-modality imaging of ovarian cancer.},
  author={Yihong Wang and Zheng Miao and Gang Ren and Yingding Xu and Zhen Cheng},
  journal={Chemical communications},
  year={2014},
  volume={50 85},
  pages={
          12832-5
        }
}
An Affibody based dual imaging probe (PET and optical imaging) has been successfully developed. Dendrimer PAMAM G0 was used as a platform to assemble an NIRF dye, a metal chelator, and Affibody for dual modality imaging of ovarian cancer. Excellent tumor imaging quality was achieved in both modalities in the living tumor mice models. 
View on PubMed
rsc.org
23 Citations
Background Citations
5
Methods Citations
2

Figures from this paper

23 Citations

Citation Type

Citation Type

Dendrimer-based contrast agents for PET imaging
TLDR
This review focuses on the recent advances in dendrimer-based contrast agents for PET imaging of cancer, cardiovascular and other diseases and radiolabeling strategies for different PET isotopes are described in detail.
Novel dual-function near-infrared II fluorescence and PET probe for tumor delineation and image-guided surgery† †Electronic supplementary information (ESI) available. See DOI: 10.1039/c7sc04774f
The first small-molecule based αvβ3-targeted NIR-II/PET dual-modal probes via base-catalyzed thiol-addition chemistry were concisely assembled and evaluated.
Gold nanoparticles for cancer theranostics — A brief update
TLDR
The developments of AuNPs as cancer diagnostics and chemotherapeutic drug vector are reviewed, summarizing strategies for tumor targeting and their applications in vitro and in vivo.
Strained cyclooctyne as a molecular platform for construction of multimodal imaging probes.
TLDR
A novel multimodal imaging platform using base-catalyzed double addition of thiols to a strained internal alkyne such as bicyclo[6.1.0]nonyne has been established in this study, thus allowing highly selective assembly of various functional units in a protecting-group-free manner.
Development of Ga-68 radiolabeled DOTA functionalized and acetylated PAMAM dendrimer-coated iron oxide nanoparticles as PET/MR dual-modal imaging agent
TLDR
Gallium-68 radiolabeled DOTA- acetyl-PAMAM coated iron oxide nanoparticles developed as dual-modality agents for PET-MR imaging showed high accumulation of candidate NPs was in the liver and spleen and about 3.4% ID/g uptake, and a distinctive uptake were observed in the tumor site.
Development of a clickable bimodal fluorescent/PET probe for in vivo imaging
TLDR
This versatile methodology has the potential to have a transformational impact on 18F radiotracer synthesis, opening the door for rapid screening of novel-labeled peptide tracers, both on the cellular (optical) as well as whole-body (PET) level.
64Cu-Labeled multifunctional dendrimers for targeted tumor PET imaging.
TLDR
The radiolabeled 64Cu-DOTA-FA-FI-G5·NHAc dendrimers can be used as a nanoprobe for specific targeting of FR-overexpressing cancer cells in vitro and targeted microPET imaging of the FR-expressing xenografted tumor model in vivo.
18F-labelled BODIPY dye as a dual imaging agent: Radiofluorination and applications in PET and optical imaging.
Radiolabeled Dendrimers for Nuclear Medicine Applications
TLDR
This review gives special focus to recent advances in dendrimer-based nuclear medicine agents for the imaging and treatment of cancer, cardiovascular and other diseases.
UPAR targeted molecular imaging of cancers with small molecule-based probes.
...
1
2
3
...

References

SHOWING 1-10 OF 35 REFERENCES
Affibody-based nanoprobes for HER2-expressing cell and tumor imaging.
Active targeting using HER-2-affibody-conjugated nanoparticles enabled sensitive and specific imaging of orthotopic HER-2 positive ovarian tumors.
TLDR
Her-2 targeted magnetic iron oxide nanoparticles are developed by conjugating a high affinity and small size HER-2 affibody that is labeled with a unique near infrared dye (NIR-830) to the nanoparticles, enabling non-invasive optical and MR imaging of tumors as small as 1 mm in the peritoneal cavity.
Affibody modified and radiolabeled gold-iron oxide hetero-nanostructures for tumor PET, optical and MR imaging.
Design of peptide imaging agents for whole-body and intraoperative molecular imaging.
TLDR
This review focused on the evolving design of peptide imaging agents starting with the clinically used somatostatin targeting peptides and the current synthetic approaches used for dual-labeled agent development and offers perspectives on optimal protection schemes that can be used for multimodal probe development.
Evaluation of four affibody-based near-infrared fluorescent probes for optical imaging of epidermal growth factor receptor positive tumors.
TLDR
It is demonstrated that Affibody proteins can be modified with different NIR fluorescent dyes and used for imaging of EGFR expressing tumors and developed are promising for further tumor imaging applications and clinical translation.
Tumor imaging using a picomolar affinity HER2 binding affibody molecule.
TLDR
A HER2-specific 6 kDa Affibody molecule with 22 pmol/L affinity that can be used for the visualization of HER2 expression in tumors in vivo using gamma camera is described and shows clear, high-contrast visualization of Her2-expressing xenografts in mice as early as 6 hours post-injection.
Influence of DOTA chelator position on biodistribution and targeting properties of (111)In-labeled synthetic anti-HER2 affibody molecules.
TLDR
The positioning of the DOTA chelator influences the cellular processing and the biodistribution pattern of radiolabeled affibody molecules, creating preconditions for imaging optimization.
Dual-Labeling Strategies for Nuclear and Fluorescence Molecular Imaging: A Review and Analysis
TLDR
The literature for dual-labeled antibodies and peptides that have been developed are summarized and key considerations for incorporating NIRF dyes into nuclear labeling strategies are highlighted.
Three Methods for 18F Labeling of the HER2-Binding Affibody Molecule ZHER2:2891 Including Preclinical Assessment
TLDR
Preliminary biologic data have identified 18F-FBA-ZHER2:2891 (also known as GE226) as a favored candidate for further development and radiochemistry automation, and a preferred radiolabeling strategy to progress for automated manufacture.
Molecular imaging of HER2-positive breast cancer: a step toward an individualized ‘image and treat’ strategy
TLDR
The new ‘image and treat’ strategy, involving assessment of target presence and distribution in an individual patient followed by optimized, target-specific drug delivery, may potentially improve efficacy of cancer treatment while reducing side effects.
...
1
2
3
4
...